Joe Chang, Director of the Stereotactic Ablative Radiotherapy Program at MD Anderson Cancer Center, shared a post on X:
“Optimal first-line treatment for EGFR-mutated mNSCLC?
- Tagrisso alone for most patients.
- Tagrisso plus chemo for high-risk patients (brain/liver mets or large size)
- Amivantamab: Ab EGFR and MET. Lazertinib: EGFR TK
Don’t forget: SABR plus Tagrisso for oligomets or oligoprogression.”
More posts featuring Joe Chang.
